MX2018010768A - Poliaminas biodisponibles. - Google Patents

Poliaminas biodisponibles.

Info

Publication number
MX2018010768A
MX2018010768A MX2018010768A MX2018010768A MX2018010768A MX 2018010768 A MX2018010768 A MX 2018010768A MX 2018010768 A MX2018010768 A MX 2018010768A MX 2018010768 A MX2018010768 A MX 2018010768A MX 2018010768 A MX2018010768 A MX 2018010768A
Authority
MX
Mexico
Prior art keywords
salts
pharmaceutical agent
pharmaceutical
bioavailable
polyamines
Prior art date
Application number
MX2018010768A
Other languages
English (en)
Inventor
R Burns Mark
Original Assignee
Aminex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aminex Therapeutics Inc filed Critical Aminex Therapeutics Inc
Publication of MX2018010768A publication Critical patent/MX2018010768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se describen sales farmacéuticas de un agente farmacéutico de poliamina protonada catiónica y un carboxilato orgánico aniónico que es hidrofóbico cuando está en forma protonada, particularmente adecuado para administración oral, donde estas sales tienen buena biodisponibilidad en formas de dosificación sólidas y pueden usarse en el tratamiento del cáncer y otras afecciones médicas para las cuales está destinado el agente farmacéutico.
MX2018010768A 2016-03-25 2017-03-20 Poliaminas biodisponibles. MX2018010768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313657P 2016-03-25 2016-03-25
PCT/US2017/023250 WO2017165313A1 (en) 2016-03-25 2017-03-20 Bioavailable polyamines

Publications (1)

Publication Number Publication Date
MX2018010768A true MX2018010768A (es) 2018-11-29

Family

ID=59899774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010768A MX2018010768A (es) 2016-03-25 2017-03-20 Poliaminas biodisponibles.

Country Status (20)

Country Link
US (3) US10632145B2 (es)
EP (2) EP3785706B1 (es)
JP (1) JP6949098B2 (es)
KR (1) KR102454783B1 (es)
CN (1) CN109069594B (es)
AU (1) AU2017236905B2 (es)
CA (1) CA3015849A1 (es)
CY (1) CY1123636T1 (es)
DK (2) DK3785706T3 (es)
EA (1) EA037149B1 (es)
ES (2) ES2836289T3 (es)
HR (1) HRP20201844T1 (es)
HU (1) HUE052620T2 (es)
IL (1) IL261512A (es)
LT (1) LT3432914T (es)
MX (1) MX2018010768A (es)
PL (1) PL3432914T3 (es)
PT (1) PT3432914T (es)
SI (1) SI3432914T1 (es)
WO (1) WO2017165313A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3432914T1 (sl) 2016-03-25 2021-01-29 Aminex Therapeutics, Inc. Biorazpoložljivi poliamini
WO2022072586A1 (en) 2020-09-30 2022-04-07 Aminex Therapeutics, Inc. Combination drug substance of polyamine transport inhibitor and dfmo
US20230321012A1 (en) * 2021-12-01 2023-10-12 Aminex Therapeutics, Inc. Methods To Treat Cancer With AMXT 1501 and DFMO

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3517M (fr) * 1962-12-07 1965-09-06 Hoffmann La Roche Médicament a base de compositions vitaminées.
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4590288A (en) 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
HU200093B (en) 1983-12-20 1990-04-28 Adam Kovacs Process for production of medical compositions against tumour
EP0187332B1 (en) 1985-01-10 1989-02-01 Molecular Diagnostics, Inc. Photochemical method of labelling nucleic acids for detection in hybridization assays
US4818770A (en) 1986-10-22 1989-04-04 Boyce Thompson Institute For Plant Research Prevention of a plant disease by specific inhibition of fungal polyamine biosynthesis
US5342945A (en) 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
JP3072108B2 (ja) 1988-12-09 2000-07-31 ダイセル化学工業株式会社 新規なポリアミン化合物及びグルタミン酸レセプター遮断剤
EP0597830A1 (en) 1989-07-03 1994-05-25 New York University Nyu Medical Center Use of polyamines as ionic-channel regulating agents
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US6743419B1 (en) 1992-12-22 2004-06-01 The Gillette Company Method of reducing hair growth employing sulfhydryl active compounds
US5648394A (en) 1993-05-27 1997-07-15 Boxall; Brian Alfred Topical composition for inhibiting hair growth
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
DE69434889D1 (de) 1994-02-08 2007-01-11 Nps Pharma Inc An einer neuen Stelle von Rezeptorabhängigen Kalziumkanälen wirkende Verbindungen zur Behandlung von neurologischen Erkrankungen
AU690195B2 (en) 1995-01-25 1998-04-23 Sealed Air Corporation Inflatable cushion and method of making same
US5583239A (en) 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
JPH09235271A (ja) 1996-02-29 1997-09-09 Suntory Ltd ポリアミン誘導体
ATE239443T1 (de) 1996-03-14 2003-05-15 Schering Plough Healthcare Präparat und verfahren zur künstlichen hautbräunung
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
US6172261B1 (en) 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US7208528B1 (en) 1997-07-15 2007-04-24 Mediquest Therapeutics, Inc. Polyamine analogues as therapeutic and diagnostic agents
CA2304557C (en) 1998-04-21 2008-12-30 Universite Laval Polyamine transport inhibitors
WO2000034226A1 (en) 1998-12-10 2000-06-15 Universite Laval Polyamine transport inhibitors
ATE308515T1 (de) 1999-02-05 2005-11-15 Oridigm Corp Antizymmodulatoren sowie deren verwendung
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
RU2002128917A (ru) 2000-03-24 2004-03-10 Медиквест Терапевтикс, Инк. (Us) Полиаминные аналоги в качестве цитотоксических агентов
USRE43327E1 (en) 2001-01-08 2012-04-24 Aminex Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US7432302B2 (en) 2001-01-08 2008-10-07 Mediquest Therapeutics, Inc. Composition containing polyamine transport inhibitor and use thereof
WO2002053519A2 (en) 2001-01-08 2002-07-11 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
US6914079B2 (en) 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7144920B2 (en) 2002-09-23 2006-12-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US6919483B2 (en) 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
CA2587344A1 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US7411002B2 (en) 2006-06-07 2008-08-12 The University Of Kansas Polycationic sulfonamides and use thereof
US20110027172A1 (en) * 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
DE102009000505A1 (de) * 2009-01-30 2010-08-05 Evonik Goldschmidt Gmbh Zusammensetzungen enthaltend Reaktionsprodukte aus Alkylamidoaminen, Alkylaminoimidazolinen und freiem Amin sowie deren Verwendung
NZ715686A (en) 2009-07-16 2017-08-25 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US20110256161A1 (en) * 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
US9439433B2 (en) * 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
SI3432914T1 (sl) 2016-03-25 2021-01-29 Aminex Therapeutics, Inc. Biorazpoložljivi poliamini

Also Published As

Publication number Publication date
US20230088829A1 (en) 2023-03-23
DK3785706T3 (da) 2023-09-11
LT3432914T (lt) 2020-12-10
EP3432914A1 (en) 2019-01-30
AU2017236905B2 (en) 2024-03-28
EP3432914A4 (en) 2019-11-13
US20190008892A1 (en) 2019-01-10
KR102454783B1 (ko) 2022-10-13
SI3432914T1 (sl) 2021-01-29
EP3785706B1 (en) 2023-06-07
ES2955255T3 (es) 2023-11-29
US10632145B2 (en) 2020-04-28
EP3432914B1 (en) 2020-09-23
CN109069594A (zh) 2018-12-21
IL261512A (en) 2018-10-31
CA3015849A1 (en) 2017-09-28
CN109069594B (zh) 2022-03-08
PL3432914T3 (pl) 2021-03-08
AU2017236905A1 (en) 2018-09-06
HRP20201844T1 (hr) 2021-04-02
ES2836289T3 (es) 2021-06-24
KR20180123133A (ko) 2018-11-14
HUE052620T2 (hu) 2021-05-28
US11395834B2 (en) 2022-07-26
DK3432914T3 (da) 2020-11-30
CY1123636T1 (el) 2022-03-24
WO2017165313A1 (en) 2017-09-28
PT3432914T (pt) 2020-12-24
US20200352983A1 (en) 2020-11-12
EP3785706A1 (en) 2021-03-03
EA037149B1 (ru) 2021-02-11
JP6949098B2 (ja) 2021-10-13
EA201892175A1 (ru) 2019-02-28
JP2019513153A (ja) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2019008127A (es) Composiciones farmaceuticas que comprenden meloxicam.
MY191574A (en) Pharmaceutical compositions comprising meloxicam
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2016001793A (es) Terapia de combinacion para el tratamiento del cancer.
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
EP3133068A4 (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
CY1123636T1 (el) Διαθεσιμες πολυαμινες
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IN2015DN01023A (es)
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1119754T1 (el) Ετεροκυκλικη ενωση αμιδιου οξικου οξεος
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3586843A4 (en) GLUCOCALYXIN A DERIVATIVE, PHARMACEUTICAL SALT THEREOF, OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF IN THE MANUFACTURING OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PSORIASIS
MX2017010304A (es) Composiciones farmaceuticas que comprenden meloxicam.
EP3153178A4 (en) Method for treating cancer patients using folr1 targeted drug and antifolate, and drug
EP3338771A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL-ETORICOXIB CHLORHYDRATE FOR THE TREATMENT OF PAIN
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη